The CellPraxis® Bioengeneering is a company that operates in the Regenerative Medicine, translating research into new treatment options.
The company is part of the Axis Biotec Group, with extensive background in R, D & I (Research, Development and Innovation) and expertise in translating scientific research into safe and commercially viable therapeutic options.
On the platform of the company, the expertise in regulatory areas, project management, intellectual property strategy provides greater efficiency with lower relative cost, representing gains due to synergy and reduction of invested capital.
The CellPraxis® is a bioengineering company that aims to launch innovative products and services in regenerative medicine and cell therapy.
The launch of products and services for orphan conditions or those without therapeutic options is an excellent opportunity.
To find, develop and deliver innovative, effective and safe treatment options in cell therapy, benefiting thousands of patients and directly increasing their longevity.
Reach a remarkable position in the new Regenerative Medicine Industry.
Innovation, ethics and quality.
Cell Therapy is already a reality
- + Urinary Incontinence
Stem cells obtaining from the menstrual fluid – transportation, isolation, characterization, expansion and cryopreservation.
Assuming that stem cells obtained from menstrual blood have the same properties as any other stem cell, we assumed to have similar transport, isolation, characterization, expansion and cryopreservation properties. These cells exhibit certain advantages over stem cells obtained from other sources, for example: easy obtaining, no ethical or moral issues and autologous treatment possibility. In this project our objective are: analyze the collection process, evaluation of cryopreservation and techniques standardization, for subsequent application in Urinary Incontinence treatment.
- + Neonatal Hypoxia
The use of autologous umbilical cord blood in neonatal asphyxia and reperfusion treatment.
Despite major advances in the ill newborns care in recent years, the prevalence of cerebral palsy due to birth asphyxia remains stable. Certainly, this reflects the current approach, based only on measures of life support. For the reduction in morbidity and mortality by asphyxiation, new therapeutic approaches to neurons protection or to restore the damaged tissue are necessary. Taking into account the few clinical trials use umbilical cord blood stem cells in neonatology and the positive potential impact on psychomotor development of affected infants, it was decided to develop this research. The main objective is to observe safety in infants and the secondary end point is to observe the possible influence of the treatment on the neurological prognosis.
- + Lipodystrophy
Development and production of a filling agent composed of biomaterial and cells obtained from autologous adipose tissue for lipodystrophies treatment.
Lipodystrophies are part of a clinically heterogeneous group of diseases characterized by loss and / or accumulation of fat that usually results in a change in contour normal tissue. Millions of plastic and reconstructive surgeries are performed annually to repair soft tissue defects resulting from trauma, tumor resection, and congenital defects. Currently, the most widely used filling agent for the treatment of lipodystrophy is polymethylmethacrylate, considered permanent and with an adverse effects history in short and medium term. This project main objective is to reach a formulation composed of mononuclear cells obtained from adipose tissue associated with a biomaterial and subsequent preclinical trial.
- + Amyotrophic Lateral Sclerosis
A randomized and double-blind phase I / II clinical trial to compare the safety and tolerability of the umbilical cord mononuclear cells intravenous double and multiple infusions with placebo in amyotrophic lateral sclerosis patients in use of riluzole.
ALS is a disease that affects individuals economically active, making them dependent on family members and helpers. More importantly, it is a fatal disease. No treatment can cure or stop the progression of the disease. As the current treatment of ALS is palliative and only one medication approved by ANVISA has limited effectiveness. New researches are necessary to develop other therapeutic methods. This study aims to determine the safety and tolerability of a new therapeutic proposal for ALS: the umbilical cord blood cells infusion. This new proposal is based on the physiological capacity of these cells to provide trophic support for affected motor neurons; in animal studies demonstrating its safety and efficacy; in clinical trials; and other research in progress. It is not possible to determine the pharmacokinetics of the mononuclear cells infusion, so the dose is based only on efficiency, which explains the absence of a prior phase I study.